Biolife Solutions (BLFS) Common Equity (2010 - 2026)

Biolife Solutions (BLFS) has 17 years of Common Equity data on file, last reported at $372.2 million in Q1 2026.

• On a quarterly basis, Common Equity rose 5.56% year-over-year to $372.2 million in Q1 2026; TTM through Mar 2026 was $372.2 million, a 5.56% increase from a year earlier, with the FY2025 full-year figure at $371.9 million, up 6.59% from the prior year.
• Common Equity for Q1 2026 stood at $372.2 million, roughly flat from $371.9 million in the prior quarter.
• Over the last five years, Common Equity for BLFS reached as high as $476.1 million in Q1 2022 and fell as low as $321.4 million in Q2 2024.
• Historically, Common Equity has averaged $362.5 million across 5 years, with a median of $352.6 million in 2025.
• Across the five-year window, Common Equity soared 128.03% in 2022 and dropped 24.78% in 2023, its largest moves.
• Year by year, Common Equity stood at $364.2 million in 2022, then decreased by 7.28% to $337.7 million in 2023, then increased by 3.33% to $348.9 million in 2024, then rose by 6.59% to $371.9 million in 2025, then grew by 0.09% to $372.2 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $372.2 million in Q1 2026, $371.9 million in Q4 2025, and $353.7 million in Q3 2025.